Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2No longer available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 3Lymphoid 3

Conditions

Mastocytosis, Systemic 3Leukemia, Myeloid, Acute 3Leukemia, Mast-Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia 2Aggression 2Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Congenital Abnormalities 1

Interventions

midostaurin 3avapritinib 2ripretinib 1nilotinib 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Ranitidine 1Interviews as Topic 1Ibuprofen 1Diphenhydramine 1Dexamethasone 1Calcium Dobesilate 1Brentuximab Vedotin 1Azacitidine 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × midostaurin × Lymphoid × Clear all
NCT05219266 2024-06-28

Managed Access Programs for PKC412, Midostaurin

Novartis

No longer available
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Novartis

Phase 2 Completed
116 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT00233454 2018-09-20

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Stanford University

Phase 2 Completed
26 enrolled 12 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡